Search PubMed⌕ Search

Biomedical subjects

R Murata

Publications and source records attributed to R Murata.

At least 109 records · Page 6Linked to original sources
PubMed1984

Trisomy 16q13----qter in a infant from a t(11;16)(q25;q13) translocation-carrier father.

A female infant with 16q trisomy resulting from a paternally inherited balanced translocation is described and compared with five previously reported cases. All the babies were of low birth weight and expired within 1 year, with only one exception. Necropsy of the present case revealed atrial septal defect, single left lobe of the lung, anomalous lobulation of the liver, agenesis of the gall bladder, and anovestibular fistula.

Abnormalities, Multiple↗
PubMed1983

Status of antitoxic immunity against diphtheria in Japan. A report of the National Epidemiological Surveillance for Important Communicable Diseases.

Antitoxic immunity against diphtheria was surveyed during the period from 1962 to 1980. The survey was done by Schick test in the first decade and then by antitoxin titration of sera by the cell culture method in the recent six years. The data show clearly that the successful control of diphtheria has been accomplished in Japan as the result of active immunization. Both single (D) and combined (DP or DPT) vaccines were effective to convert Schick reaction negative. In addition, immunity was greatly improved by the introduction of the combined vaccine and one additional booster injection. However, such subsequent changes in the immunization schedule introduced in 1976 that giving the primary vaccination at older age and the omission of one booster injection at the preschool, has resulted in appearance of a high risk group below three years of age as well as in the lower immunity levels among school children. The data indicate that the continuous surveillance for diphtheria is required in this country.

Adolescent↗
PubMed1981

The diagnostic value of cerebrospinal fluid lactic acid levels in meningitis.

To assess the reliability of cerebrospinal fluid (CSF) lactate levels in children for differentiating between bacterial and viral meningitis, we measured the CSF lactate levels using the carboxylic acid analyzer, enzymatic method and colorimetric determination. Lactate determination by these methods is a highly reliable indicator of the presence or absence of bacterial meningitis. Moreover, the duration of elevated CSF lactate levels coincided with the clinical response to therapy.

Child↗
PubMed1981

Immune response of man to Habu-venom toxoid.

Immune response of man to various Habu-venom toxoids with different potencies was investigated. A linear relationship was observed between circulating anti-HRI and the amount of HRI toxoid used for the basic immunization. A highly purified toxoid was 2.5 times more effective in man than partially purified ones, when compared on the basis of the immunizing unit determined in guinea pigs. Out of 265 vaccinees, 202 (76.2%) produced anti-HRI exceeding 1 U/ml after two injections of the mixed toxoid and the rate rose to 96% after the booster immunization, when the preparation contained HR1 toxoid of not less than 9 ImU per dose. The rate fell to 58% and 28.5%, 12 months and 24 months after the last injection, respectively. Although booster immunization was effective to restore the declined antibody production, the level of anti-HR1 after the injection did not exceed that after the basic immunization in the groups primed with partially purified HR1 toxoid. Neither increased number of injection nor changed duration of intervals of successive injections for the basic immunization improved the immune response of man. Booster effect was slightly higher in the groups primed with a highly purified toxoid, but its magnitude was much smaller than that in the case of other kinds of toxoid (e.g. tetanus toxoid). Anti-HR2 was invariably higher than 1 U/ml, being more than 5-10 U/ml in many vaccinees. However, the behavior after the booster injection was similar to that of anti-HR1. Side reaction was not a serious obstacle in continuing immunization. The volunteers amounted to 8,206, but general reactions were rare, if any. However, allergic reactions of the vaccinees should carefully be checked, since repeated booster immunization may be necessary to maintain immunity.

Antibody Formation↗
PubMed1981

Immunogenicity of purified Habu snake-venom toxoid in guinea pigs and monkeys with special reference to HR1 component.

Purity of the parent toxin influenced greatly the immunogenicity in guinea pigs of HR1 component of Habu-venom toxoid. The potency of HR1 toxoid in terms of the immunizing unit (ImU) appeared to be related to the antigen and aluminum contents. The immune response of the animals differed depending on the purity of the toxoid when the dose-response curve was examined over a wide range of the antigen dosage. Anti-HR1 titers of the guinea pigs immunized with crude toxoid (adsorbed) reached a plateau at about 10-20 U/ml ane further rise was not remarkable even when the amout of the antigen was increased several times, while 200 U/ml (maximum 400 U/ml or higher) of annti-HR1 was produced with a large amount of highly purified HR1 toxoid. Purified toxoid showed an excellent immunogenicity also in monkeys. The amounts of antigens necessary for the basic immunization to resist the challenge with a certainly lethal dose of crude venom were 18 and 0.5 mg as protein, for a crude and a highly purified toxoid, respectively. The total amount of aluminum was also reduced from 8.1 (crude toxoid) to 0.5 mg (purified toxoid). Multiple injections for the primary immunization enhanced early production of anti-HR1 in monkeys. However, at later stage of immunization, significant correlation was observed between the amount of HR1 toxoid (in ImU) for the primary immunization and the circulating anti-HR1 titer irrespective of the schedule of immunization. Anti-HR2 higher than 10 U/ml was produced consistently in monkeys with HR2 toxoid of 1.0 ImU for the basic immunization. However, excess HR2 toxoid of more than 10 ImU seemed rather unfavorable for anti-HR2 production.

Aluminum↗